Compare AMETEK, Inc. (AME) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Danaher Corporation — how do they compare? AMETEK, Inc. trades at $258.19 (market cap $58.76B), while Danaher Corporation trades at $205.77 (market cap $145.83B). The key difference: Danaher Corporation is far larger — about 2.5× AMETEK, Inc.'s market cap, and Danaher Corporation pays the higher dividend (0.77%). Which is the better fit depends on your goals.
| AME | DHR | |
|---|---|---|
Market Cap | $58.76B | $145.83B |
Sector | Industrials | Health |
52-Week High | $256.30 | $242.05 |
52-Week Low | $179.28 | $161.91 |
Enterprise Value | $60.30B | $168.04B |
Dividend Yield | 0.53% | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $252.88, down 0.31% on the day, with a bullish technical signal from moving averages and strong support near $252. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance, reflecting robust demand. Revenue grew to $7.4B in 2025, with a net margin of 20.04%, while valuation ratios like P/E of 37.47 suggest a premium. Recent news highlights momentum and inclusion in high-growth themes like 3D printing.
Outlook remains positive given earnings beats and analyst consensus, but risks include elevated valuation and macroeconomic sensitivity. The stock offers growth potential with a $281.86 price target, though investors should monitor execution against guidance and industry competition.
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
